Literature DB >> 2598993

Determination of acetylator phenotype in Caucasians with caffeine.

M Hildebrand1, W Seifert.   

Abstract

Acetylator status in 595 healthy Caucasian volunteers was determined with caffeine. The test group consisted of 372 males and 223 females, 18 to 78 years of age. 312 volunteers were smokers. Caffeine was taken orally as Coffein Comprette (200 mg caffeine x H2O) and urine was collected for 8 h. The metabolic ratio (MR) of 5-acetylamino-6-formylamino-1-methyluracil (AFMU) to 1-methylxanthine (MX) was determined by HPLC. In total 61.7% of the group had a MR less than 0.48 and were classified as slow acetylators. MR varied from 0.01 to 0.47 in the slow acetylators and from 0.48 to 4.7 in the fast acetylator group. Clear dependence of acetylator type upon age, sex or smoking behaviour was not observed. The present study has confirmed the caffeine test as a feasible tool to determine acetylation capacity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2598993     DOI: 10.1007/bf00558136

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Metabolism of isoniazid in man as related to the occurrence of peripheral neuritis.

Authors:  H B HUGHES; J P BIEHL; A P JONES; L H SCHMIDT
Journal:  Am Rev Tuberc       Date:  1954-08

2.  Mass phenotyping of isoniazid inactivators by automated determination of acetylisoniazid in urine.

Authors:  P Varughese; E J Hamilton; L Eidus
Journal:  Clin Chem       Date:  1974-06       Impact factor: 8.327

3.  Variability in caffeine metabolism.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-05       Impact factor: 6.875

Review 4.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

5.  Determination of procainamide acetylator status.

Authors:  J J Lima; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1978-01       Impact factor: 6.875

6.  Polymorphic acetylation procainamide in man.

Authors:  M M Reidenberg; D E Drayer; M Levy; H Warner
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

7.  Polymorphic N-acetylation of a caffeine metabolite.

Authors:  D M Grant; B K Tang; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875

8.  An alternative test for acetylator phenotyping with caffeine.

Authors:  B K Tang; D Kadar; W Kalow
Journal:  Clin Pharmacol Ther       Date:  1987-11       Impact factor: 6.875

9.  Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.

Authors:  T B Vree; W J O'Reilly; Y A Hekster; J E Damsma; E van der Kleijn
Journal:  Clin Pharmacokinet       Date:  1980 May-Jun       Impact factor: 6.447

10.  Determination of dextromethorphan metabolizer phenotype in healthy volunteers.

Authors:  M Hildebrand; W Seifert; A Reichenberger
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

View more
  2 in total

1.  Host factors in occupational diisocyanate asthma: a Swiss longitudinal study.

Authors:  M Berode; M Jost; M Ruegger; H Savolainen
Journal:  Int Arch Occup Environ Health       Date:  2005-02-16       Impact factor: 3.015

2.  Clinical and Molecular Risk Factors of Anti-tubercular Therapy Induced Hepatitis.

Authors:  Premashis Kar; Rahul Karna; Rajesh Ruttala; Shilpa Arora; Anita Chakravarty; Suresh Kumar
Journal:  J Clin Exp Hepatol       Date:  2018-06-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.